Full-Time
Provides scientific tools for life sciences
No salary listed
Entry, Junior
Manchester, NH, USA
Hybrid position requiring 3 days onsite.
Upload your resume to see how it matches 9 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
LGC Group provides scientific tools and solutions that support advancements in healthcare and pharmaceuticals. Their products include oligo components, probes, primers, and recombinant viral materials, which are essential for detecting diseases and developing vaccines and therapies for various illnesses, including cancer and infectious diseases like COVID-19. LGC serves a wide range of clients, such as healthcare professionals and pharmaceutical companies, and generates revenue through the sale of these specialized tools and proficiency testing schemes that ensure food safety. What sets LGC apart from competitors is its strong focus on quality and innovation, which helps improve healthcare outcomes and contributes to a safer world.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
London, United Kingdom
Founded
1841
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
Remote Work Options
Graham B Jackson Pty Ltd (GBJPL), an Australian leader in reference materials, partners with the globally renowned LGC Group to supply high-quality CRMs to laboratories across the country.
For example, LGC Group introduced a proficiency testing (PT) service in April 2020 that uses nucleic acid amplification testing to identify SARS-CoV-2 (COVID-19).
UK-based LGC, an international life sciences measurement and tools company, has appointed Joydeep Goswami as president and CEO, succeeding Euan O'Sullivan, who decided to step down from his role in early 2024 after fourteen years of service.
LGC acquires DiaMex to drive innovation and choice for core laboratory customers: acquisition complements LGC's serology and molecular quality control portfolio and enhances choice of products from a single supplier.
London, UK – 4 December 2024 – LGC today announces an addition to its growing global clinical diagnostics and genomics portfolio, following the acquisition of DiaMex, a manufacturer of third-party serology and molecular quality controls used in clinical laboratories and blood banks across the world.